Revenue segments as reported by the company.

Technology & Analytics Solutions

Research & Development Solutions

Contract Sales & Medical Solutions

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative expenses

Depreciation and amortization

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

IQVIA Hlds

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment, which primarily serves biopharmaceutical customers, provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the broader healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IQVIA reports solid Q4 performance, addresses macro challenges proactively

IQVIA delivered a strong performance in Q4 2022 with revenue growth, operational achievements, and solid financial guidance for 2023, underlining its market position and strategic focus.
While facing challenges from macroeconomic factors, wage inflation, and market conditions, the company is proactively addressing these issues through cost-cutting measures and debt reduction strategies.
By leveraging its strengths in stable operations, record bookings, and financial discipline, IQVIA aims to navigate challenges, capitalize on opportunities, and drive sustainable growth in the future.

IQVIA reports solid Q1 growth amidst industry challenges and opportunities

IQVIA Hlds (IQV) Q1 2023 reflects strong financial performance and operational resilience.
Challenges in backlog burn and industry dynamics are being managed effectively.
Opportunities in M&A activity and demand for real-world evidence drive growth.
Steady guidance for 2023 positions the company well for future success.

IQVIA posts strong Q2 results, eyes growth amid AI investments

IQVIA's Q2 performance reflects solid growth and strategic wins in data and analytics solutions.
While facing challenges in decision delays and economic uncertainties, the company's AI investments and strong R&DS segment offer growth opportunities.
With a focus on leveraging AI across business areas and a vast patient data advantage, IQVIA is well-positioned for future success.

IQVIA reports mixed Q3 results, eyes growth through strategic initiatives

IQVIA's Q3 2023 performance showcased strength in R&DS bookings and revenue growth, while TAS faced challenges from foreign exchange and weak demand. The company aims to drive growth through new contracts, cost reduction initiatives, and strategic pricing adjustments, with a focus on stabilizing performance and pursuing growth opportunities in 2024.

IQVIA reports robust Q4 earnings, eyes growth amid challenges

IQVIA's strong performance in bookings and revenue growth positions it well for future success.
While facing challenges in TAS and pricing negotiations, IQVIA's contract wins and guidance for 2024 show resilience.
Opportunities lie in improving demand for TAS, increasing RFPs, and growth in the data business.
Overall, IQVIA's strategic wins and financial outlook indicate a positive trajectory for the company.

IQVIA reports solid Q1 performance, eyes growth through partnerships

IQVIA delivered a solid performance in Q1 2024, meeting revenue expectations and showcasing growth in bookings and pipeline. The company's strengths lie in technology-enabled solutions, global partnerships, and public health initiatives.
Challenges include cancellations impacting revenue, pricing pressures, and the need to navigate market dynamics. However, IQVIA's opportunities in innovation, partnerships, and market expansion position it well for future growth.
Overall, IQVIA's strategic focus on technology, client engagements, and public health initiatives, amidst challenges in cancellations and pricing pressures, presents a resilient outlook. The company's financial performance and industry leadership are key strengths.
With a proactive approach to challenges and a focus on seizing opportunities, IQVIA remains well-positioned for sustained growth and success in the evolving healthcare landscape. The company's adaptability and strategic initiatives drive confidence in its future prospects.

IQVIA reports robust Q2 earnings, eyes growth amidst market challenges

IQVIA Hlds delivered a strong Q2 performance with revenue and earnings growth, supported by efficient operations and solid financial metrics.
While facing challenges such as pricing pressures and market dynamics, the company remains optimistic about future opportunities and growth potential.
Strategic focus on addressing challenges and seizing opportunities will be key to sustaining performance and maximizing shareholder value in the dynamic healthcare landscape.

IQVIA Hlds reports Q3 growth, faces study delays and pricing challenges

IQVIA Hlds demonstrated solid financial performance in Q3 2024, driven by revenue growth and increased EPS.
While facing challenges like study delays and pricing pressures, the company's strategic strengths and opportunities for growth remain intact.
With a focus on share buybacks and R&DS growth, IQVIA is positioning itself for sustained success in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.

IQVIA's (IQV) revenues are likely to increase year over year on the back of improving segmental performance.

IQVIA (IQV) to Report Q3 Earnings: What's in the Offing?

IQVIA (IQV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IQVIA Holdings (IQV) Expected to Beat Earnings Estimates: Should You Buy?

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the pharmaceutical and broader life sciences industry, today announced that Sanofi will use the IQVIA OCE platform in select countries across Africa and the Middle East. IQVIA OCE is a next-generation life sciences commercial platform that connects all customer-facing functions to deliver more personalized and optimized custome.

IQVIA to Provide Sanofi Its Orchestrated Customer Engagement (OCE) Platform in Africa & Middle East

DexCom

Edwards Lifesciences

Insulet

Medical Product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EW, PODD, DXCM and IQV are poised ahead of their earnings release.

4 Medical Product Stocks Set to Outpace Q3 Earnings Estimates

RESEARCH TRIANGLE PARK, N.C. & OSLO, Norway--(BUSINESS WIRE)--IQVIA, (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services, and The Coalition for Epidemic Preparedness Innovations (CEPI) today announced a strategic collaboration to advance the 100 Days Mission. In conjunction with national and regional collaborators, CEPI and IQVIA will aim to enhance the world's preparedness to rapidly conduct life-saving clinical research for vaccine.

IQVIA and CEPI Collaborate to Strengthen Global Research Preparedness to Advance the 100 Days Mission

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its third-quarter 2023 financial results before the market opens on Wednesday, November 1, 2023. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentati.

IQVIA to Announce Third-Quarter 2023 Results on November 1, 2023

IQVIA (IQV) and argenx expand collaboration to advance rare autoimmune treatments through innovative pharmacovigilance.

IQVIA (IQV) and argenx Partner to Advance Autoimmune Care

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a strategic collaboration with argenx to advance treatment to patients with rare autoimmune diseases through innovative and integrated technology-enabled pharmacovigilance (PV) safety services and solutions. IQVIA's integrated PV services and technology platforms will support argenx t.

IQVIA Builds on its Strategic Collaboration with argenx to Provide Safety Systems and Services

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has appointed Richard Staub III, currently senior advisor to the Chairman and CEO, as president of its Research & Development Solutions (R&DS) business unit. Richard is a vastly experienced executive with 34 years in the life science sector and has held numerous senior exec.

IQVIA Appoints Richard Staub III President of Research & Development Solutions

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a global provider of data, analytics, technology solutions and services to the life sciences industry, has been named a Leader in the IDC Marketscape Worldwide Life Science R&D Pharmacovigilance Solutions 2022 Vendor Assessment. Fueled by IQVIA Connected Intelligence™, IQVIA offers a full suite of PV technologies and services to support end-to-end safety processes, including the SaaS-based Vigilance Platform which can harness.

IQVIA Named a Leader in Pharmacovigilance Solutions in IDC MarketScape Report

An addressable market size and strong healthcare-specific global IT infrastructure boost IQVIA (IQV).

Here's Why Investors Should Retain IQVIA (IQV) Stock Now

Gilead Sciences

abrdn Healthcare Investors 

iShares Nasdaq Biotechnology ETF

Illumina

Direxion Daily S&P Biotech Bull 3X Shares

Lonza Group AG

Merck

Navistar

Omega Healthcare Investors

Pfizer

Royalty Pharma

abrdn World Healthcare Fund 

Wuxi Biologics Cayman Inc

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

The recent IRA list of 10 drug publications is not expected to have a significant impact on big pharma stocks in the near term. The legal challenges by big pharma companies against the IRA may derail the implementation of the drug pricing reforms. Investors can consider diversified biotech indexes or healthcare-focused ETFs for exposure to the biopharma sector.

Biopharma Bounce-Back: From Policy Pains To Profitable Plains

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Baird 2023 Global Healthcare Conference in New York City on Wednesday, September 13, 2023 at 10:50 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About IQVIA I.

IQVIA CFO Ron Bruehlman to Speak at Baird Global Healthcare Conference on September 13, 2023

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ari Bousbib, chairman and chief executive officer, will speak at the Morgan Stanley Annual Global Healthcare Conference in New York City on Tuesday, September 12, 2023 at 11:30 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About IQVIA IQVIA (NYS.

IQVIA CEO Ari Bousbib to Speak at Morgan Stanley Annual Global Healthcare Conference on September 12, 2023

IQVIA (IQV) reported earnings 30 days ago. What's next for the stock?

IQVIA (IQV) Up 2.5% Since Last Earnings Report: Can It Continue?

Eli Lilly

Madrigal Pharmaceuticals

This year has not been kind to biotech stocks, as the sector's most popular ETF, the iShares Biotechnology ETF (NASDAQ: IBB ), has fallen about 3% so far in 2023. Investors are probably worried about the impact of higher interest rates and potential reforms by Washington, DC on the sector.

3 Biotech Stocks That Wall Street Analysts Can't Get Enough Of

IQVIA (IQV) aims at market expansion through innovation and service improvements.

IQVIA (IQV) Stock Improves 8% in Three Months: Here's How

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

West Pharmaceutical Services

Zoetis

For investors, tracking the stocks that are up in what has otherwise been a grim year for drugmakers can help identify trends in the market.

In a Tough Year for Pharma, These 6 Stocks Are Shining

IQVIA Holdings Inc. (NYSE:IQV ) Q2 2023 Earnings Conference Call August 1, 2023 9:00 AM ET Company Participants Nick Childs - SVP, IR and Treasurer Ari Bousbib - Chairman and CEO Ron Bruehlman - EVP and CFO Conference Call Participants David Windley - Jefferies Ann Hynes - Mizuho Eric Coldwell - Baird Tejas Savant - Morgan Stanley Luke Sergott - Barclays Shlomo Rosenbaum - Stifel Jailendra Singh - Truist Operator Ladies and gentlemen, thanks for standing by. At this time, I would like to welcome everyone to the IQVIA Second Quarter 2023 Earnings Conference Call.

IQVIA Holdings Inc. (IQV) Q2 2023 Earnings Call Transcript

IQVIA Holdings (IQV) second-quarter 2023 revenues improve year over year.

IQVIA Holdings' (IQV) Q2 Earnings Beat Estimates, Decline Y/Y

Although the revenue and EPS for IQVIA (IQV) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

IQVIA (IQV) Reports Q2 Earnings: What Key Metrics Have to Say

IQVIA Holdings (IQV) came out with quarterly earnings of $2.43 per share, beating the Zacks Consensus Estimate of $2.37 per share. This compares to earnings of $2.44 per share a year ago.

IQVIA Holdings (IQV) Surpasses Q2 Earnings and Revenue Estimates

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended June 30, 2023. Second-Quarter 2023 Operating Results Revenue for the second quarter of $3,728 million increased 5.3 percent on a reported basis and 5.5 percent at constant currency, compared to the second quarter of 2022.

IQVIA Reports Second-Quarter 2023 Results

IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate IQVIA Holdings (IQV) to Report a Decline in Earnings: What to Look Out for

Aptiv Holdings Ltd

Trane Technologies plc

The Zacks Technology Services industry seeks to benefit from the increased dependency on technology, digitization and the growing adoption of the multi-cloud model. TT, IQV and APTV are well poised to witness a demand surge.

News for IQVIA Hlds Stock (IQV)